Expertise in
25
conditions

Dr. William R. Wilcox

Medical Genetics
2165 N Decatur Rd, 
Decatur, GA 
Accepting New Patients
Expertise in
25
conditions
2165 N Decatur Rd, 
Decatur, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Wilcox is a Medical Genetics provider in Decatur, Georgia. Dr. Wilcox is highly rated in 25 conditions, according to our data. His top areas of expertise are Fabry Disease, Achondroplasia, Mucopolysaccharidoses (MPS), and Multiple Sulfatase Deficiency. Dr. Wilcox is currently accepting new patients.

His clinical research consists of co-authoring 66 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Medical Genetics
Licenses
Clinical Genetics in GA
Languages Spoken
English
Arabic
Italian
Portuguese
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions

Accepted plan types not found. Please verify directly with the provider.

CareSource
  • HMO
Centene

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid

Accepted plan types not found. Please verify directly with the provider.

Medicaid

Accepted plan types not found. Please verify directly with the provider.

Medicare

Accepted plan types not found. Please verify directly with the provider.

Oscar
  • EPO
  • HMO
  • PPO
Silverscript

Accepted plan types not found. Please verify directly with the provider.

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
WellCare Health Plans

Accepted plan types not found. Please verify directly with the provider.

View 10 Less Insurance Carriers -

Locations

2165 N Decatur Rd, Decatur, GA 30033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Enrollment Status: Terminated
Publish Date: December 30, 2024
Intervention Type: Drug
Study Drug: Venglustat GZ402671
Study Phase: Phase 3
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the US
Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the US
Enrollment Status: Available
Publish Date: August 16, 2024
Intervention Type: Drug
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
Enrollment Status: Active_not_recruiting
Publish Date: May 09, 2024
Intervention Type: Biological
Study Drug: ST-920
Study Phase: Phase 1/Phase 2
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2024
Intervention Type: Biological
Study Drug: 4D-310
Study Phase: Phase 1/Phase 2
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drug: Pegunigalsidase Alfa
Study Phase: Phase 3
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drug: AGT-181
Study Phase: Phase 1
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)
Enrollment Status: Terminated
Publish Date: January 26, 2023
Intervention Type: Biological
Study Drug: SB-318
Study Phase: Phase 1/Phase 2
An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 12 to <18 Years) With Fabry Disease and Amenable GLA Variants
An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 12 to <18 Years) With Fabry Disease and Amenable GLA Variants
Enrollment Status: Completed
Publish Date: November 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
MPS VI Clinical Surveillance Program (CSP)
MPS VI Clinical Surveillance Program (CSP)
Enrollment Status: Completed
Publish Date: April 05, 2021
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

66 Total Publications

Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension.
Safety and efficacy of migalastat in adolescent patients with Fabry disease: Results from ASPIRE, a phase 3b, open-label, single-arm, 12-month clinical trial, and its open-label extension.
Journal: Molecular genetics and metabolism
Published: October 03, 2024
Similar Doctors
Expertise in
2
conditions
Dr. Juanita N. Neira-Fresneda
Medical Genetics
Expertise in
2
conditions
Dr. Juanita N. Neira-Fresneda
Medical Genetics
1365 Clifton Rd Ne, Building B Suite 2200, 
Atlanta, GA 
 (1.0 mi)
404-778-8570
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Juanita Neira-Fresneda is a Medical Genetics provider in Atlanta, Georgia. Dr. Neira-Fresneda is highly rated in 2 conditions, according to our data. Her top areas of expertise are Potocki-Lupski Syndrome, Smith-Magenis Syndrome, Trisomy 17 Mosaicism, and Phenylketonuria (PKU). Dr. Neira-Fresneda is currently accepting new patients.

Expertise in
9
conditions
Dr. Jaime E. Vengoechea-Barrios
Medical Genetics | Pediatrics
Expertise in
9
conditions
Dr. Jaime E. Vengoechea-Barrios
Medical Genetics | Pediatrics

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (1.0 mi)
404-778-7525
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Jaime Vengoechea-Barrios is a Medical Genetics specialist and a Pediatrics provider in Atlanta, Georgia. Dr. Vengoechea-Barrios is highly rated in 9 conditions, according to our data. Their top areas of expertise are Megalencephalic Leukoencephalopathy with Subcortical Cysts, Multiple Sulfatase Deficiency, Pompe Disease, and Danon Disease. Dr. Vengoechea-Barrios is currently accepting new patients.

Expertise in
2
conditions
Dr. Michael J. Gambello
Medical Genetics | Pediatrics
Expertise in
2
conditions
Dr. Michael J. Gambello
Medical Genetics | Pediatrics

The Emory Clinic Inc

1365 Clifton Rd Ne, 
Atlanta, GA 
 (1.0 mi)
404-778-7525
Languages Spoken:
English, Arabic, French, Italian, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Gambello is a Medical Genetics specialist and a Pediatrics provider in Atlanta, Georgia. Dr. Gambello is highly rated in 2 conditions, according to our data. His top areas of expertise are Cortical Dysplasia, Short-Chain Acyl-CoA Dehydrogenase Deficiency, Increased Head Circumference, and Focal or Multifocal Malformations in Neuronal Migration. Dr. Gambello is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wilcox's expertise for a condition
ConditionClose
View All 23 Advanced Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile